Matica Bio at BIO International 2024: Leading the Way in CGT Innovation and U.S. Manufacturing Strategy
May 22 2024 - 11:18AM
Business Wire
Highlighting Advanced CGT Capabilities and
Strategic U.S. Manufacturing Position Amidst Rising Geopolitical
Tensions
Matica Biotechnology (Matica Bio) announced today that it will
participate in the world’s largest biotech exhibition, the BIO
International Convention (BIO USA).
The BIO International Convention is one of the largest events
for the global bio industry, with more than 20,000 delegates
attending and over 57,000 partnering meetings hosted last year. BIO
is growing annually and is expected to reach record attendance and
meetings this year.
Matica Bio: Growth and Expansion
Matica Biotechnology (Matica Bio) is proud to highlight its
global sites and expertise in Cell and Gene Therapy (CGT)
development and manufacturing at this year's BIO International
Convention. Matica Bio built a U.S. CGT specialized facility and
expanded its advanced scientific capabilities to be able to provide
excellent results and a white-glove level of service for clients.
Matica Bio is looking forward to numerous scheduled meetings with
existing and potential clients at BIO USA to pursue contracts and
explore collaborative opportunities.
Matica Bio's facility is uniquely designed and constructed
exclusively for cell and gene therapy manufacturing. As a leading
CDMO, Matica Bio offers tailored services that ensure seamless CGT
development and manufacturing from preclinical through clinical
stages. In collaboration with Sartorius, a global bioprocessing
leader, Matica Bio employs single-use systems and in-line,
real-time process analytical monitoring and testing. Furthermore,
its proprietary cell line, MatiMax™, significantly enhances
manufacturing efficiency and productivity.
Matica Bio also collaborates with four other production
facilities within the CHA Bio Group: Bundang CHA Hospital GMP,
Matica Bio Labs, Cell Gene Biobank, and Matica Bio Japan. These
five worldwide sites will work together to offer comprehensive CGT
services, drive continued expansion, reduce production costs, and
extend the company's reach across Asia and North America.
Matica Bio’s Role in the U.S. Biosecure Act
In response to increasing geopolitical tensions and supply chain
vulnerabilities, the U.S. government has recently implemented the
Biosecure Act. This Act has highlighted the strategic importance of
domestic manufacturing capabilities and protection of the U.S.
national health security. The reduced dependency on certain foreign
CDMOs positions Matica Bio for substantial growth and greater
success this year and beyond.
Paul Kim, CEO of Matica Bio said, "Leveraging its professional
capability and expertise, Matica Bio offers seamless service from
gene to clinic. This strategic positioning ensures that Matica Bio
not only adheres to the Biosecure Act but also maintains an
uninterrupted supply chain for its clients, enhancing its
competitive edge in the market.”
Collaborative Efforts within CHA Bio Group
Also under the CHA Bio Group umbrella, CHA Biotech, CMG
Pharmaceuticals, and CHA Vaccine Research Institute will jointly
present their development pipelines and technologies at BIO USA,
focusing on technology transfer and collaboration opportunities.
CHA Biotech will promote its NK cell-based cancer immunotherapy
‘CBT101’ and explore CAR technology, while CHA Vaccine Research
Institute will seek partners for its immune-enhancing hepatitis B
and shingles vaccines. CMG Pharmaceuticals will highlight its
STARFILM Technology-based Orally Disintegrating Film (ODF)
products, including Depipzo, NaraPhil ODF, and Zedafil, aiming for
business partnerships to expand exports. Cha Bio Group’s
participation underscores its commitment to biotechnological
innovation, excellence, and global expansion.
The BIO International Convention will take place in San Diego
from June 3rd to 6th, and Matica Bio will exhibit at booth
#4757.
About Matica Biotechnology, Inc.
Matica Biotechnology is a cell and gene therapy CDMO that
leverages advanced technologies at its purpose-built cGMP facility.
With industry-leading expertise in process development, assay
development, and cGMP manufacturing, Matica Bio serves as a trusted
partner, seamlessly supporting its clients with streamlined
operations throughout every stage of projects. Collaborating across
five Matica sites worldwide, Matica Bio delivers excellence in the
CDMO domain through innovations such as MatiMax™ proprietary cell
lines, in-line process monitoring, and single-use technologies.
Visit www.maticabio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522020107/en/
Yeni Choi Senior Director of Marketing Matica Biotechnology
yeni.choi@maticabio.com